* Jasper Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 10 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.22 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.
* Wall Street's median 12-month price target for Jasper Therapeutics Inc is $65.00, above its last closing price of $22.77.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.60 -1.61 -1.50 Beat 7.1
Sep. 30 2023 -1.53 -1.55 -1.60 Missed -3.1
Jun. 30 2023 -1.81 -1.50 -1.50 Met -0.1
Mar. 31 2023 -1.64 -1.62 -1.60 Beat 1.5
Dec. -3.51 -3.60 -3.60 Met 0
31 2022
Sep. 30 2022 -3.40 -3.42 -3.20 Beat 6.6
Jun. 30 2022 -3.23 -3.13 -2.90 Beat 7.4
Mar. 31 2022 -3.49 -3.50 -0.60 Beat 82.9
This summary was machine generated May 8 at 11:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments